29 related articles for article (PubMed ID: 29076659)
1. Beyond
Farago AF; Azzoli CG
Transl Lung Cancer Res; 2017 Oct; 6(5):550-559. PubMed ID: 29114471
[TBL] [Abstract][Full Text] [Related]
2. Reactive histiocytic proliferation in the pleural fluid mimicking metastatic signet ring adenocarcinoma.
Mir F; Naumaan A; Alnajar H; Brickman A; Reddy V; Park JW; Gattuso P
Diagn Cytopathol; 2018 Jun; 46(6):525-527. PubMed ID: 29316379
[TBL] [Abstract][Full Text] [Related]
3. Cytological features in eight patients with ALK-rearranged lung cancer.
Kuroda N; Ohara M; Wada Y; Yasuoka K; Mizuno K; Yorita K; Obayashi C; Takeuchi K
Diagn Cytopathol; 2018 Jun; 46(6):516-519. PubMed ID: 29280331
[TBL] [Abstract][Full Text] [Related]
4. High feasibility of cytological specimens for detection of
Zhang L; Wang Y; Zhao C; Shi J; Zhao S; Liu X; Jia Y; Zhu T; Jiang T; Li X; Zhou C
Onco Targets Ther; 2019; 12():3305-3311. PubMed ID: 31118681
[TBL] [Abstract][Full Text] [Related]
5. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
Vlajnic T; Savic S; Barascud A; Baschiera B; Bihl M; Grilli B; Herzog M; Rebetez J; Bubendorf L
Cancer Cytopathol; 2018 Jun; 126(6):421-429. PubMed ID: 29451745
[TBL] [Abstract][Full Text] [Related]
6. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers.
Yoshida A; Tsuta K; Wakai S; Arai Y; Asamura H; Shibata T; Furuta K; Kohno T; Kushima R
Mod Pathol; 2014 May; 27(5):711-20. PubMed ID: 24186139
[TBL] [Abstract][Full Text] [Related]
8. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A
Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
[TBL] [Abstract][Full Text] [Related]
9. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
Park E; Choi YL; Ahn MJ; Han J
Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
[TBL] [Abstract][Full Text] [Related]
10. Cytological findings of ROS1-rearranged lung adenocarcinoma.
Kuroda N; Tamiya H; Nakatani K; Ide H; Wada Y; Yasuoka K; Ohara M; Mizuno K; Yorita K; Takeuchi K
Diagn Cytopathol; 2018 Apr; 46(4):336-339. PubMed ID: 29076659
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
Luk PP; Selinger CI; Mahar A; Cooper WA
Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067
[TBL] [Abstract][Full Text] [Related]
12. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
